“Paradoxical” Findings of Tumor Vascularity and Oxygenation in Recurrent Glioblastomas Refractory to Bevacizumab

Oncotarget - United States
doi 10.18632/oncotarget.21978
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Impact Journals, LLC

Related search

Addition of Lomustine for Bevacizumab-Refractory Recurrent Glioblastoma

Acta Oncologica
Nuclear MedicineRadiologyHematologyOncologyMedicineImaging
2014English

Efficacy of Bevacizumab Therapy in Recurrent Malignant Gliomas in Relation to the Prior Recurrence Pattern or Tumor Location

Journal of Clinical Neuroscience
MedicineSurgeryNeurologyPhysiology
2017English

Bevacizumab for Recurrent Hemangioendothelioma

Acta Oncologica
Nuclear MedicineRadiologyHematologyOncologyMedicineImaging
2010English

Antithrombotics and Bleeding Risk: Paradoxical Findings

The Lancet Neurology
Neurology
2019English

147. Evaluation of Tumor Vascularity Using DSA

Nippon Hoshasen Gijutsu Gakkai zasshi
Medicine
1993English

Sustained Focal Antitumor Activity of Bevacizumab in Recurrent Glioblastoma

Neurology
Neurology
2014English

Bevacizumab Monotherapy for Temozolomide-Refractory Malignant Glioma

Japanese Journal of Neurosurgery
SurgeryNeurology
2010English

Erratum To: Single-Agent Bevacizumab Is an Effective Treatment in Recurrent Glioblastoma

Medical Oncology
MedicineCancer ResearchOncologyHematology
2015English

Neutrophilic Steroid-Refractory Recurrent Wheeze and Eosinophilic Steroid-Refractory Asthma in Children

Journal of Allergy and Clinical Immunology: In Practice
AllergyImmunology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy